Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | TPO | P07202 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LPO | P22079 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893581 | 0.89 | GPR84 (0.59) | BACE1GPR84CYP1A2MAPTLMNA | |
| SCHEMBL27845668 | 0.86 | SMN1; SMN2 (0.54) | BACE1GPR84CYP1A2ALDH1A1LMNA | |
| SCHEMBL1889337 | 0.83 | PKM (0.56) | BACE1GPR84CYP1A2MAPTALDH1A1 | |
| SCHEMBL1892022 | 0.81 | HTT (0.67) | BACE1GPR84CYP1A2MAPTSMN1; SMN2 | |
| SCHEMBL17241037 | 0.79 | GPR84 (0.49) | GPR84CYP1A2MAPTALDH1A1NPSR1 | |
| SCHEMBL7153368 | 0.77 | GPR84 (0.69) | BACE1GPR84GSK3B | |
| SCHEMBL15107929 | 0.75 | SMN1; SMN2 (0.69) | BACE1CYP1A2MAPTALDH1A1LMNA | |
| SCHEMBL12349347 | 0.74 | GPR84 (0.46) | BACE1GPR84CYP1A2MAPTALDH1A1 | |
| SCHEMBL8937121 | 0.73 | LMNA (0.51) | BACE1CYP1A2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6998274 | 0.73 | LMNA (0.47) | BACE1CYP1A2ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998968-B2 | Substituted pyrimidines and [1,2, 4] triazoles and the use thereof for treating prophylaxis, cardiovascular diseases, metabolic diseases and/or central nervous system diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20110112120-A9 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-05-12 | — | — | US | disclosed |
| EP-2256115-A1 | Heteromonocyclic compound and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7803940-B2 | Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20100113780-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-06 | — | — | US | disclosed |
| US-20100105709-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-04-29 | — | — | US | disclosed |
| US-20100056526-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-03-04 | — | — | US | disclosed |
| WO-2009133970-A1 | CRYSTALLINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-05 | — | — | WO | disclosed |
| US-20090176812-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-07-09 | — | — | US | disclosed |
| EP-2074117-A2 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-20080207654-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-08-28 | — | — | US | disclosed |
| WO-2008062905-A2 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112120-A9 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C1S, C3AR1 | BACE1 2170/4885GPR84 385/4885CYP1A2 437/4885 |
| US-20100113780-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C1S, C3AR1 | BACE1 2170/4885GPR84 385/4885CYP1A2 437/4885 |
| US-20100056526-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | CYP11B2, CYP11B1, NR3C2 | BACE1 1246/4885GPR84 902/4885CYP1A2 128/4885 |
| US-20080207654-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C3AR1, C1S | BACE1 2459/4885GPR84 360/4885CYP1A2 498/4885 |
| US-20090176812-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C1S, C3AR1 | BACE1 2170/4885GPR84 385/4885CYP1A2 437/4885 |
| US-20100105709-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C1S, C3AR1 | BACE1 2170/4885GPR84 385/4885CYP1A2 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.